Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

  • user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: DELETE FROM cache_filter WHERE expire != 0 AND expire <= 1283575165 in /persistent/html/includes/cache.inc on line 23.
  • user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:1444085e73920221208fee34405f9934' in /persistent/html/includes/cache.inc on line 26.
  • user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = '<p>This is a phase III study of BMS-354825 in subjects with chronic phase Philadelphia chromosome or BCR-ABL positive chronic myelogenous leukemia, who are resistant or intolerant to imatinib mesylate (Gleevec).</p>\n', created = 1283575468, expire = 1283661868, headers = '', serialized = 0 WHERE cid = '1:1444085e73920221208fee34405f9934' in /persistent/html/includes/cache.inc on line 109.
  • user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:0b89925ea88339a84c7a7176af80e54c' in /persistent/html/includes/cache.inc on line 26.
  • user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = '<p>A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic My</p>\n', created = 1283575468, expire = 1283661868, headers = '', serialized = 0 WHERE cid = '1:0b89925ea88339a84c7a7176af80e54c' in /persistent/html/includes/cache.inc on line 109.
  • user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:cc7819055cde3194bb3b136bad5cf58d' in /persistent/html/includes/cache.inc on line 26.
  • user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = '<p>&nbsp;</p>\n', created = 1283575468, expire = 1283661868, headers = '', serialized = 0 WHERE cid = '1:cc7819055cde3194bb3b136bad5cf58d' in /persistent/html/includes/cache.inc on line 109.
  • user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:35957d00dc3ac37c4dac7ce8f5b0bd19' in /persistent/html/includes/cache.inc on line 26.
  • user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = '<p>Inclusion Criteria:\n<ul>\n<li>Subjects with Philadelphia chromosome positive (Ph+) (or BCR/ABL+) chronic phase chronic myeloid leukemia whose disease has primary or acquired hematologic resistance to imatinib mesylate or who are intolerant of imatinib mesylate.</li>\n<li>Men and women, 18 years or older</li>\n<li>Adequate hepatic function</li>\n<li>Adequate renal function</li>\n<li>Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month before and at least 3 months after the study in such a manner that the risk of pregnancy is minimized.</li>\n</ul>\n</p><p> Exclusion Criteria:\n<ul>\n<li>Women who are pregnant or breastfeeding</li>\n<li>Subjects who are eligible and willing to undergo transplantation during the screening period</li>\n<li>A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy</li>\n<li>Uncontrolled or significant cardiovascular disease</li>\n<li>Medications that increase bleeding risk</li>\n<li>Medications that change heart rhythms</li>\n<li>Dementia or altered mental status that would prohibit the understanding or rendering of informed consent</li>\n<li>History of significant bleeding disorder unrelated to CML</li>\n<li>Concurrent incurable malignancy other than CML</li>\n<li>Evidence of organ dysfunction or digestive dysfunction that would prevent administration of study therapy</li>\n<li>Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study</li>\n</ul>\n</p>', created = 1283575468, expire = 1283661868, headers = '', serialized = 0 WHERE cid = '1:35957d00dc3ac37c4dac7ce8f5b0bd19' in /persistent/html/includes/cache.inc on line 109.
  • user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:2e54b28a2e7a0d78e8c6ac5eb29ff7a4' in /persistent/html/includes/cache.inc on line 26.
  • user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = '<p>Progression free and overall survival [&nbsp;Time&nbsp;Frame:&nbsp;throughout the study&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]</p>\n', created = 1283575468, expire = 1283661868, headers = '', serialized = 0 WHERE cid = '1:2e54b28a2e7a0d78e8c6ac5eb29ff7a4' in /persistent/html/includes/cache.inc on line 109.
  • user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: SELECT data, created, headers, expire, serialized FROM cache_filter WHERE cid = '1:2dd1dc0356d5a06aecba4360d82491a3' in /persistent/html/includes/cache.inc on line 26.
  • user warning: Table './intheclinic/cache_filter' is marked as crashed and should be repaired query: UPDATE cache_filter SET data = '<p>Comparison of Major Cytogenetic Response rate between two dose levels [&nbsp;Time&nbsp;Frame:&nbsp;throughout the study&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]</p>\n', created = 1283575468, expire = 1283661868, headers = '', serialized = 0 WHERE cid = '1:2dd1dc0356d5a06aecba4360d82491a3' in /persistent/html/includes/cache.inc on line 109.
Trial phase: 
Phase III
Recruitment status: 
Active, not recruiting

This is a phase III study of BMS-354825 in subjects with chronic phase Philadelphia chromosome or BCR-ABL positive chronic myelogenous leukemia, who are resistant or intolerant to imatinib mesylate (Gleevec).

Background information
Trial ID: 
NCT00123474
Other unique IDs: 
CA180-034
Official title: 

A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic My

Detailed description: 

 

Number to be enrolled: 
670 patients
Clinical information
Age groups: 
Adult
Senior
Gender: 
Both
Eligibility criteria: 

Inclusion Criteria:

  • Subjects with Philadelphia chromosome positive (Ph+) (or BCR/ABL+) chronic phase chronic myeloid leukemia whose disease has primary or acquired hematologic resistance to imatinib mesylate or who are intolerant of imatinib mesylate.
  • Men and women, 18 years or older
  • Adequate hepatic function
  • Adequate renal function
  • Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month before and at least 3 months after the study in such a manner that the risk of pregnancy is minimized.

Exclusion Criteria:

  • Women who are pregnant or breastfeeding
  • Subjects who are eligible and willing to undergo transplantation during the screening period
  • A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy
  • Uncontrolled or significant cardiovascular disease
  • Medications that increase bleeding risk
  • Medications that change heart rhythms
  • Dementia or altered mental status that would prohibit the understanding or rendering of informed consent
  • History of significant bleeding disorder unrelated to CML
  • Concurrent incurable malignancy other than CML
  • Evidence of organ dysfunction or digestive dysfunction that would prevent administration of study therapy
  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study

Study design: 
Treatment
Randomized
Safety/Efficacy Study
Open Label
Parallel Assignment
Dose Comparison
Interventions: 
Dasatinib
Conditions treated: 
Myeloid Leukemia, Chronic, Chronic-Phase
Outcome measurements: 

Progression free and overall survival [ Time Frame: throughout the study ] [ Designated as safety issue: No ]

Comparison of Major Cytogenetic Response rate between two dose levels [ Time Frame: throughout the study ] [ Designated as safety issue: No ]

Funding
Funding types: 
INDUSTRY
Sponsor: 
Bristol-Myers Squibb
Dates
Date the data was first received: 
Thu, 2005-07-21
Trial start date: 
Fri, 2005-07-01
Trial completion date: 
Fri, 2011-04-01
Trial last updated: 
Wed, 2009-05-20